News
Click here for news in Danish.
May 16, 2018 | Press Releases
Bavarian Nordic Announces Acceptance of Abstracts and Oral Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting September 14, 2017 | Press Releases
Bavarian Nordic to Host Capital Markets Day in New York CitySeptember 11, 2017 | Press Releases
Principal Investigator Dr. James Gulley to Provide Presentation Entitled “Therapeutic Vaccines in Prostate Cancer” at the ESMO 2017 Congress April 19, 2017 | Press Releases
Bavarian Nordic Announces Initiation of Phase 2 Combination Trial of PROSTVAC, Ipilimumab and Nivolumab in Patients with Localized Prostate CancerDecember 29, 2016 | Press Releases
Bavarian Nordic Initiates Trial of CV301 in Combination with Nivolumab in Patients with Lung CancerDecember 14, 2016 | Press Releases
Bavarian Nordic Announces Completion of Enrollment for Phase 2 Clinical Trial of RSV Vaccine October 10, 2016 | Press Releases
Bavarian Nordic Announces Initiation of Phase 2 Combination Trial of PROSTVAC and Ipilimumab in Patients with Localized Prostate CancerSeptember 29, 2016 | Press Releases
Bavarian Nordic Announces Presentation of Phase 1 Data for its RSV Vaccine at International RSV SymposiumSeptember 28, 2016 | Press Releases
Bavarian Nordic Appoints Christopher Heery, M.D., as Chief Medical OfficerSeptember 12, 2016 | Press Releases
Bavarian Nordic Announces that Janssen has completed a Submission for Emergency Use Assessment and Listing for its Ebola Vaccine Regimen to the World Health OrganizationApril 19, 2016 | Press Releases
Bavarian Nordic Applauds Announcement of Positive Data for Ebola Vaccine Regimen Published in JAMAFebruary 04, 2016 | Press Releases
Bavarian Nordic Enters Research Collaboration to Develop MRSA VaccineOctober 28, 2015 | Press Releases
Bavarian Nordic Applauds Recommendations Outlined by U.S. Blue Ribbon Study Panel on Biodefense May 21, 2015 | Press Releases
Members of the management and the board increase their share holdings in Bavarian Nordic A/SSeptember 04, 2014 | Press Releases
Bavarian Nordic Accelerates Ebola Vaccine Development Programs in Collaboration with the U.S. National Institutes of HealthApril 23, 2014 | Press Releases
Bavarian Nordic Announces Activities Around the 2014 ASCO Annual MeetingNovember 15, 2013 | Press Releases
Bavarian Nordic Completes Delivery of 20 Million Doses of IMVAMUNE® Smallpox Vaccine to the U.S. Strategic National StockpileJuly 01, 2013 | Press Releases
Bavarian Nordic CEO Anders Hedegaard Elected as Co-Chair of the Alliance for BiosecurityMay 27, 2013 | Press Releases
Bavarian Nordic Announces Presentation of PROSTVAC® at the 2013 ASCO Annual MeetingMarch 05, 2013 | Press Releases
Bavarian Nordic Applauds Reauthorization of Key U.S. Biodefense ProgramsJune 02, 2012 | Press Releases
Interim Analysis for Bavarian Nordic’s Phase 2 PROSTVAC® Trial Presented at Annual ASCO MeetingMay 22, 2012 | Press Releases
U.S. Government Supports Phase 3 Study of Bavarian Nordic’s Smallpox VaccineMay 18, 2012 | Press Releases
Bavarian Nordic to Report New PROSTVAC® Clinical Data at the American Society of Clinical Oncology Annual MeetingOctober 12, 2011 | Press Releases
Bavarian Nordic's IMVAMUNE® Smallpox Vaccine Highlighted as Success Story in WMD Center's Bio-Response Report CardSeptember 15, 2011 | Press Releases
New Scientific Publication Supports Advantages of Bavarian Nordic’s Poxviral Cancer Immunotherapy Platform